Dual-Targeted Thalidomide Nanoliposomes Suppress Neutrophil-Driven Inflammation in Intestinal Behçet’s Disease
Excessive neutrophil recruitment, vascular activation, and platelet-associated inflammatory interfaces are implicated in intestinal tissue injury in intestinal Behçet's disease (intestinal BD), whereas conventional systemic therapies offer limited spatial control over drug exposure within active intestinal lesions. Here, we developed thalidomide-loaded nanoliposomes co-functionalized with a neutrophil elastase-binding peptide (NEBP) and a P-selectin-binding peptide (PSN), designated Thd-NEBP/PSN-Lip, to engage complementary activated neutrophil-associated and P-selectin-associated inflammatory interfaces. Thd-NEBP/PSN-Lip exhibited a mean hydrodynamic diameter of 116.6 ± 5.7 nm, a thalidomide encapsulation efficiency of 91.43 ± 0.71%, and reduced initial burst release, while maintaining colloidal stability during storage and simulated gastrointestinal exposure. Surface ligand density was estimated from the feed composition. Ligand-dependent interactions were observed in activated endothelial cells and neutrophil-like cells; in activated endothelial cells, liposome-associated fluorescence increased from 7.42% for Thd-Lip to 40.55% for Thd-NEBP/PSN-Lip and decreased to 1.10% following free PSN competition. Additional validation supported PSN-dependent association with activated platelets and greater inflamed-tissue association of the dual-ligand formulation than with either single-ligand formulation. In vivo, Thd-NEBP/PSN-Lip showed preferential and prolonged retention within inflamed intestinal tissues, with intestinal fluorescence remaining approximately 2.6-fold higher than that of Thd-Lip at 24 h. LC-MS/MS quantification further showed increased total intestinal thalidomide exposure and a higher intestine/plasma concentration ratio after Thd-NEBP/PSN-Lip administration. In a murine intestinal BD-like model, Thd-NEBP/PSN-Lip alleviated intestinal injury, restored colon length toward the healthy level, reduced neutrophil infiltration and local inflammatory cytokine expression, attenuated responses involving IL-17A+CD4+ and IFN-γ+CD4+ T cells, and partially restored the Foxp3+ regulatory T cell compartment. Microbiome, metabolomic, and transcriptomic analyses further indicated broader treatment-associated changes in the intestinal inflammatory microenvironment. Collectively, these findings suggest that dual-targeted nanoliposomes improve lesion-directed thalidomide delivery and suppress neutrophil-driven intestinal inflammation, supporting a pathology-guided nanotherapeutic strategy for intestinal BD.
Authors
- Kaichao Song (ORCID: https://orcid.org/0000-0003-3461-6033)
- Peng Lei
- Fujun Zeng (ORCID: https://orcid.org/0009-0006-0308-8097)
- 郑稳生
- Ya Meng
- HE Shuwang
- Rou Tang (ORCID: https://orcid.org/0000-0001-7605-0379)
- Zhenhua Li (ORCID: https://orcid.org/0000-0001-9871-2257)
- Wu Dong
- Xiaochuan Tan (ORCID: https://orcid.org/0000-0002-1134-6846)
- Yige Yang
- Yujia Zhang
- Kun He
- Lu Lu
- Shuo Chen
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
- China Medical University (CN)
Publication Details
- Journal
- ACS Applied Materials & Interfaces
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1021/acsami.6c15386
- Primary Topic
- Nanoparticle-Based Drug Delivery
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Peking Union Medical College